Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Clin Epidemiol ; 14: 879-888, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35879942

RESUMO

Objective: Data on the risk of ischemic heart disease (IHD) in patients with chronic hepatitis B virus (CHB) are conflicting. Our objective was to address the rate of IHD in patients with CHB compared with individuals without CHB (control-persons) from the general population. Study Design and Setting: We conducted a cohort study of prospectively obtained data from Danish nationwide registries. We produced cumulative incidence curves and calculated the unadjusted incidence rate ratio (IRR) of IHD in persons with and without CHB. The adjusted association between having CHB and developing IHD was examined using a cause-specific Cox regression model. Results: In total, 6472 persons with CHB and 62,251 age- and sex-matched individuals from the general population were followed for 48,840 and 567,456 person-years, respectively, during which 103 (1,59%) with CHB and 1058 (1,70%) control-persons developed IHD. The crude IRR was 1.13 (95% CI: 0.91-1.39). CHB did not have a statistically significant effect on the rate of IHD after adjusting for several confounding factors (adjusted hazard ratio: 0.96, 95% CI: 0.76-1.21). Conclusion: In this nationwide cohort study, we did not find any difference between rate of IHD in persons with CHB in comparison with the general population.

2.
PLoS One ; 15(12): e0243725, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33301499

RESUMO

BACKGROUND AND AIMS: To evaluate the ability of pretreatment liver stiffness measurements (pLSM) to predict hepatocellular carcinoma (HCC), incident decompensation and all-cause mortality in chronic hepatitis C (CHC) patients who achieved sustained virological response (SVR) after treatment with direct-acting antivirals (DAAs). METHODS: 773 CHC patients with SVR after DAA treatment and no prior liver complications were identified retrospectively. Optimized cut-off of 17.5 kPa for incident HCC was selected by maximum Youden's index. Patients were grouped by pLSM: <10 kPa [reference], 10-17.4 kPa and ≥17.5 kPa. Primary outcomes were incident hepatocellular carcinoma and secondary outcomes were incident decompensated cirrhosis and all-cause mortality, analyzed using cox-regression. RESULTS: Median follow-up was 36 months and 43.5% (336) had cirrhosis (LSM>12.5 kPa). The median pLSM was 11.6 kPa (IQR 6.7-17.8, range 2.5-75) and pLSM of <10 kPa, 10-17.4 kPa and 17.5-75 kPa was seen in 41.5%, 32.2% and 26.3%. During a median follow-up time of 36 months, 11 (1.4%) developed HCC, 14 (1.5%) developed decompensated cirrhosis, and 38 (4.9%) patients died. A pLSM of 17.5 kPa identified patients with a high risk of HCC with a negative predictive value of 98.9% and incidence rate of HCC in the 17.5-75 kPa group of 1.40/100 person years compared to 0.14/100 person years and 0.12/100 person years in the 10-17.4 kPa and <10 kPa groups, p<0.001. CONCLUSION: Pretreatment LSM predicts risk of HCC, decompensation and all-cause mortality in patients with SVR after DAA treatment. Patients with a pLSM <17.5 kPa and no other risk factors for chronic liver disease appear not to benefit from HCC surveillance for the first 3 years after treatment. Longer follow-up is needed to clarify if they can be safely excluded from post treatment HCC screening hereafter.


Assuntos
Antivirais/uso terapêutico , Carcinoma Hepatocelular/etiologia , Hepatite C Crônica/complicações , Hepatite C Crônica/tratamento farmacológico , Neoplasias Hepáticas/etiologia , Adulto , Carcinoma Hepatocelular/patologia , Carcinoma Hepatocelular/virologia , Feminino , Seguimentos , Hepacivirus/efeitos dos fármacos , Hepacivirus/isolamento & purificação , Hepatite C Crônica/patologia , Hepatite C Crônica/virologia , Humanos , Incidência , Fígado/patologia , Fígado/virologia , Cirrose Hepática/complicações , Cirrose Hepática/patologia , Cirrose Hepática/virologia , Neoplasias Hepáticas/patologia , Neoplasias Hepáticas/virologia , Masculino , Pessoa de Meia-Idade , Resposta Viral Sustentada
3.
Ugeskr Laeger ; 182(9)2020 02 24.
Artigo em Dinamarquês | MEDLINE | ID: mdl-32138816

RESUMO

In Denmark, about 50% of patients with chronic hepatitis C virus (HCV) infection are undiagnosed. Since 2014, therapy containing direct-acting antivirals (DAA) has proven efficient and is available to all patients, who have a chronic HCV infection and a Danish personal identification number. The World Health Organization has a goal of elimination of viral hepatitis in 2030. Elimination of HCV in Denmark should focus on reducing HCV transmission, incidence and prevalence, combined with treatment with DAA of all infected patients. Micro-elimination strategies may play a major role, but a national strategy is lacking.


Assuntos
Hepatite C Crônica , Hepatite C , Antivirais/uso terapêutico , Dinamarca/epidemiologia , Hepacivirus , Hepatite C/tratamento farmacológico , Hepatite C/epidemiologia , Hepatite C/prevenção & controle , Hepatite C Crônica/tratamento farmacológico , Hepatite C Crônica/epidemiologia , Hepatite C Crônica/prevenção & controle , Humanos
4.
Hepatology ; 66(6): 1794-1804, 2017 12.
Artigo em Inglês | MEDLINE | ID: mdl-28688129

RESUMO

People with hepatitis C virus (HCV) infection who have failed treatment with an all-oral regimen represent a challenging treatment population. The present studies evaluated the safety and efficacy of grazoprevir, ruzasvir, and uprifosbuvir, with or without ribavirin, in participants who had failed an NS5A inhibitor-containing regimen. C-SURGE (PN-3682-021) and C-CREST Part C (PN-3682-011 and -012) were open-label, multicenter studies. Participants who had previously relapsed following an NS5A inhibitor-containing all-oral regimen were retreated with grazoprevir 100 mg, ruzasvir 60 mg, and uprifosbuvir 450 mg alone for 24 weeks or with ribavirin for 16 weeks. The primary efficacy endpoint was sustained virologic response (HCV RNA below the limit of quantitation [<15 IU/mL]) 12 weeks after treatment completion (SVR12). In C-SURGE, SVR12 was achieved by 49/49 (100%) and 43/44 (98%) genotype (GT)1 participants in the 24-week no ribavirin arm and the 16-week plus ribavirin arm (lost to follow-up, n = 1), respectively. In C-CREST Part C, SVR12 was achieved by 23/24 (96%) participants treated for 16 weeks with ribavirin (GT1, 2/2 [100%]; GT2, 13/14 [93%]; GT3, 8/8 [100%]). One participant with GT2 infection discontinued study medication after a single dose of grazoprevir, ruzasvir, and uprifosbuvir plus ribavirin due to serious adverse events of vomiting and tachycardia. The presence of baseline resistance-associated substitutions had no impact on SVR12. No participant who completed treatment in either study experienced virologic failure. CONCLUSION: Grazoprevir, ruzasvir, and uprifosbuvir, with or without ribavirin, for 16 or 24 weeks was safe and highly effective in participants with HCV infection who had previously failed NS5A inhibitor-containing therapy. (Hepatology 2017;66:1794-1804).


Assuntos
Antivirais/uso terapêutico , Hepatite C/tratamento farmacológico , Adulto , Idoso , Quimioterapia Combinada , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Falha de Tratamento , Resultado do Tratamento
5.
Ugeskr Laeger ; 177(13): V12140669, 2015 Mar 23.
Artigo em Dinamarquês | MEDLINE | ID: mdl-25822815

RESUMO

Autoimmune hepatitis is characterized by unresolving inflammation and fibrosis of the liver, which untreated may lead to cirrhosis. The pathogenesis remains unclear and reflects a complex interaction between autoantigens, genetic predisposition, triggering factors and immune regulation. In rare cases, acute hepatitis A has been suspected as a triggering factor. We describe a case of a 66-year-old woman who two months after a resolving acute hepatitis A presented with fatigue, pale stools and elevated levels of transaminases. A liver biopsy showed histological changes compatible with autoimmune hepatitis.


Assuntos
Hepatite A/complicações , Hepatite Autoimune/etiologia , Idoso , Feminino , Humanos
6.
Dan Med J ; 59(1): C4371, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-22239847

RESUMO

National guidelines for treatment of ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, and hyponatremia have been approved by the Danish Society of Gastroenterology and Hepatology. Ascites develops in approximately 60% of patients with cirrhosis during a 10 year period and is frequently associated with complications that determine the course of the disease and the prognosis. These evidence-based guidelines are divided in two parts and consider definitions, pathophysiology, diagnostic aspects, treatment, and prophylaxis.


Assuntos
Antibacterianos/uso terapêutico , Ascite , Diuréticos/uso terapêutico , Cirrose Hepática/complicações , Paracentese/métodos , Peritonite , Ascite/diagnóstico , Ascite/etiologia , Ascite/metabolismo , Ascite/fisiopatologia , Ascite/terapia , Líquido Ascítico/metabolismo , Líquido Ascítico/microbiologia , Infecções Bacterianas/diagnóstico , Infecções Bacterianas/microbiologia , Infecções Bacterianas/fisiopatologia , Infecções Bacterianas/terapia , Protocolos Clínicos/normas , Terapia Combinada , Medicina Baseada em Evidências/normas , Humanos , Cirrose Hepática/fisiopatologia , Testes de Sensibilidade Microbiana , Peritonite/diagnóstico , Peritonite/microbiologia , Peritonite/fisiopatologia , Peritonite/terapia , Supuração/complicações , Supuração/fisiopatologia
7.
Dan Med J ; 59(1): C4372, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-22239848

RESUMO

National guidelines for treatment of ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, and hyponatremia have been approved by the Danish Society of Gastroenterology and Hepatology. Ascites develops in approximately 60% of patients with cirrhosis during a 10 year period and is frequently associated with complications that determine the course of the disease and the prognosis. These evidence-based guidelines are divided in two parts and consider definitions, pathophysiology, diagnostic aspects, treatment, and prophylaxis.


Assuntos
Diuréticos , Hidratação , Síndrome Hepatorrenal/terapia , Hiponatremia/terapia , Lipressina/análogos & derivados , Injúria Renal Aguda/etiologia , Injúria Renal Aguda/fisiopatologia , Protocolos Clínicos/normas , Contraindicações , Diuréticos/administração & dosagem , Diuréticos/efeitos adversos , Medicina Baseada em Evidências/normas , Hidratação/efeitos adversos , Hidratação/métodos , Hidratação/normas , Síndrome Hepatorrenal/diagnóstico , Síndrome Hepatorrenal/etiologia , Síndrome Hepatorrenal/metabolismo , Síndrome Hepatorrenal/fisiopatologia , Humanos , Hiponatremia/etiologia , Hiponatremia/metabolismo , Hiponatremia/fisiopatologia , Cirrose Hepática/complicações , Cirrose Hepática/fisiopatologia , Lipressina/administração & dosagem , Lipressina/efeitos adversos , Insuficiência Renal Crônica/etiologia , Insuficiência Renal Crônica/fisiopatologia , Terlipressina , Vasoconstritores/administração & dosagem , Vasoconstritores/efeitos adversos , Desequilíbrio Hidroeletrolítico/etiologia , Desequilíbrio Hidroeletrolítico/fisiopatologia
8.
Clin Epidemiol ; 3 Suppl 1: 3-10, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21814464

RESUMO

OBJECTIVE: Primary liver cancer (PLC) is a serious disease with high mortality. During the last decade, improvements in the diagnostic procedures and treatment of PLC may have improved survival. However, few updated longitudinal studies examined this issue. In a population-based setting, we studied changes in the prognoses over time. METHODS: Between 1998 and 2009, we identified all patients with PLC in the central and northern Denmark regions, with a combined population of 1.8 million. We determined age- and period-stratified survival, and computed mortality rate ratios (MRRs) with 95% confidence intervals (CIs), using Cox proportional hazard regression to assess changes over time, while controlling for age and gender. We conducted the analyses for PLC overall and separately for hepatocellular carcinoma (HCC) and cholangiocarcinoma, respectively. RESULTS: We included 1064 patients with PLC. Their median age was 69 years (range 17-94 years). The number of patients diagnosed with PLC in the period 2007-2009 was approximately 40% higher than the number in 1998-2000. One-year survival increased from 16% in 1998-2000 to 28% in 2007-2009, corresponding to an adjusted 1-year MRR of 0.65 (95% CI: 0.54-0.79). In patients aged <60 years, we found the most pronounced increase in 1-year survival, from 14% to 49% in women and from 19% to 41% in men. The 3- and 5-year survival in the entire cohort increased from 5% to a predicted 11% and from 2% to a predicted 7% during our study period, respectively. Accordingly, the expected 3- and 5-year adjusted MRRs were 0.68 (95% CI: 0.57-0.82) and 0.68 (95% CI: 0.57-0.81), respectively. One-, 3-, and 5-year survival improved during the study period for both HCC and cholangiocarcinoma. CONCLUSION: PLC survival remains poor in the Danish population, although we observed an increase over the period 1998-2009, particularly in young people.

9.
Scand J Gastroenterol ; 46(7-8): 988-96, 2011 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-21612322

RESUMO

OBJECTIVE: Alterations of the electroencephalogram (EEG) have been reported in patients with hepatic encephalopathy (HE). However, previous methods have not assessed transient phenomena in the EEG signal (dynamics) and associations to psychometric test performance have in general been poor. The aims were to quantify spectral and dynamic EEG abnormalities in patients with HE and to correlate putative findings to psychometric test performances. METHODS: Multichannel EEG (64 electrodes) was recorded in 24 cirrhotic patients with various grades of HE and 26 healthy volunteers. Spectral and dynamic EEG indices were quantified by continues wavelet analysis. In addition, the psychometric hepatic encephalopathy score (PHES), continues reaction time, and biochemical profile were assessed. RESULTS: Compared with healthy volunteers, patients had progressively slowing of the EEG (all p ≤ 0.004) (spectral EEG indices) and increased variability in the alpha [7.5-13.5 Hz] (p = 0.001) and beta bands [13.5-32 Hz] (p = 0.02) (dynamic EEG indices). In addition, anteriorization and dissociation of the basic posterior alpha rhythm, along with dissociation of frontal delta activities [1-3.5 Hz] were seen with worsening of HE. Spectral EEG indices (all frequency bands) as well as dynamic EEG indices (alpha and beta bands) were correlated to PHES scores (all p < 0.05). CONCLUSION: EEG analysis, based on continues wavelet transform, provides quantifiable information on static as well as dynamic features of the EEG in patients with HE. EEG abnormalities were correlated to psychometric test performance and may provide valuable clinical biomarkers for surveillance, prognostication and treatment of this entity.


Assuntos
Eletroencefalografia/métodos , Encefalopatia Hepática/fisiopatologia , Encefalopatia Hepática/psicologia , Testes Neuropsicológicos , Análise de Ondaletas , Amônia/sangue , Análise de Variância , Feminino , Encefalopatia Hepática/etiologia , Humanos , Cirrose Hepática/complicações , Masculino , Pessoa de Meia-Idade , Tempo de Reação/fisiologia , Índice de Gravidade de Doença
10.
Eur J Gastroenterol Hepatol ; 22(11): 1323-30, 2010 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-20661140

RESUMO

BACKGROUND AND AIM: Hepatic encephalopathy (HE) is a severe and frequent complication of liver cirrhosis characterized by abnormal cerebral function. Little is known about the underlying neural mechanisms in HE and human data are sparse. Electrophysiological methods such as evoked brain potentials after somatic stimuli can be combined with inverse modeling of the underlying brain activity. Thereby, information on neuronal dynamics and brain activity can be studied in vivo. The aim of this study was to investigate the sensory brain processing in patients with HE. PATIENTS AND METHODS: Twelve patients with minimal or overt HE and 26 healthy volunteers were included in the study. Cerebral sensory processing was investigated as (i) an auditory reaction time task; (ii) visual and somatosensory evoked brain potentials, and (iii) reconstruction of the underlying brain activity. RESULTS: Somatosensory evoked potentials were reproducible (all P>0.05), whereas flash evoked potentials were not reproducible (all P<0.05). Compared with healthy volunteers, the patient group had a prolonged reaction time index (P=0.03) along with increasing prolongation of latencies of median nerve evoked potentials (P<0.03). Reconstruction of the underlying brain sources showed a lateral shift in source localization of the P45 (P<0.001) and N60 components (P=0.02). A correlation between the psychometric hepatic encephalopathy score and the dipole shift corresponding to the N60 (P=0.003) component was seen. CONCLUSION: HE patients have evidence of prolonged intracerebral nerve conduction, along with lateralization of brain activity following median nerve stimulation. This possibly represents cortical reorganization and may be important in our understanding of this condition.


Assuntos
Ondas Encefálicas , Encéfalo/fisiopatologia , Encefalopatia Hepática/fisiopatologia , Estimulação Acústica , Idoso , Percepção Auditiva , Mapeamento Encefálico , Estudos de Casos e Controles , Dinamarca , Estimulação Elétrica , Eletroencefalografia , Potenciais Somatossensoriais Evocados , Potenciais Evocados Visuais , Feminino , Lateralidade Funcional , Encefalopatia Hepática/diagnóstico , Humanos , Masculino , Nervo Mediano/fisiopatologia , Pessoa de Meia-Idade , Condução Nervosa , Testes Neuropsicológicos , Estimulação Luminosa , Psicometria , Tempo de Reação , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...